Plasmodium Vivax

A new malaria vaccine has been found to generate robust immune response although it could not altogether prevent infection, according to a first of its kind in-human study.

The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market SynriamTM in India for the treatment of uncomplicated malaria in adults caused by Plasmodium vivax parasite, Ranbaxy Laboratories Ltd said in a statement.

A new malaria vaccine has been found to generate robust immune response although it could not altogether prevent infection, according to a first of its kind in-human study.

The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market SynriamTM in India for the treatment of uncomplicated malaria in adults caused by Plasmodium vivax parasite, Ranbaxy Laboratories Ltd said in a statement.